Majd A El-Harasis, Zachary T Yoneda, Katherine C Anderson, Fei Ye, Joseph A Quintana, J Roberto Martinez-Parachini, Gregory G Jackson, Bibin T Varghese, Diane M Crawford, Lili Sun, Hollie L Williams, Matthew J O'Neill, Giovanni E Davogustto, James L Laws, Brittany S Murphy, Kelsey Tomasek, Yan Ru Su, Emily McQuillen, Emma Metz, Carly Smith, Doug Stubbs, Dakota D Grauherr, Quinn S Wells, Gregory F Michaud, Pablo Saavedra, Juan Carlos Estrada, Travis D Richardson, Sharon T Shen, Arvindh N Kanagasundram, Jay A Montgomery, Harikrishna Tandri, Christopher R Ellis, George H Crossley, Prince J Kannankeril, Lynne W Stevenson, William G Stevenson, Steven A Lubitz, Patrick T Ellinor, Dan M Roden, M Benjamin Shoemaker
BACKGROUND: Patients with rare, pathogenic cardiomyopathy (CM) and arrhythmia variants can present with atrial fibrillation (AF). The efficacy of AF ablation in these patients is unknown. OBJECTIVE: This study tested the hypotheses that: 1) patients with a pathogenic variant in any CM or arrhythmia gene have increased recurrence following AF ablation; and 2) patients with a pathogenic variant associated with a specific gene group (arrhythmogenic left ventricular CM [ALVC], arrhythmogenic right ventricular CM, dilated CM, hypertrophic CM, or a channelopathy) have increased recurrence...
August 20, 2024: JACC. Clinical Electrophysiology